New Vaccines for Autoimmune and Chronic Inflammatory Conditions: Advances, Challenges, and Future Directions

Medicine & Health TRANSNATIONAL JOURNAL Volume IV│ Issue 4 │ 2025 ISSN: 2692-1936 November-December Transnational Journal of Medicine & Health Volume IV │Issue 4 │October-December London, WC28 5AH 2025 Transnational Journal of Medicine & Health Editorial Team Editors-in-Chief 1. Dr. Skender Topi, University 'Aleksander Xhuvani' Elbasan, Albania 2. Katerina Ristoska, Hemodialysis Center of Sistina Nefroplus. Skopje. Macedonia. Editorial board members/reviewers 1. M.D. Ervin Rapushi, University Hospital Center "Mother Theresa" Department of Internal Medicine. Service of Rheumatology, Tirana, Albania 2. Sachin Kumar Samuchiwal, Brigham and Women's Hospital. Harvard Medical School, Boston, MA, United States 3. Associate Professor Rustem Celami, University Aldent, Tirana, Albania 4. Yau Sui Yu, The Open University of Hong Kong, Hong Kong 5. Behzad Foroutan, Shahroud University of Medical Sciences, Shahroud, Iran 6. Dr. Amer Taqa, DBS Dept. College of Dentistry, University of Mosul, Iraq 7. Sc. M.D. Denisa Golemi, Lushnja Regional Hospital, Lushnja, Albania 8. Marco Orsini, Federal Fluminense University, Rio de Janeiro, Brazil 9. Ravi Teja Mandapaka, National Institute of Nutrition, Hyderabad, India 10. Dr. Prema Saldanha, Yenepoya Medical College, Mangalore, India 11. Associate Professor Fadil Gradica, University of Medicine Tirana, Tirana, Albania 12. Associate Professor Besim Boçi, University of Medicine in Tirana, Tirana, Albania 13. M.D. Petraq Mustaqe, American Hospital Fier, Fier, Albania 14. Prof. Assoc. Dr. Admir Jançe, European University of Tirana, Technical Medical Sciences Faculty, Tirana, Albania Transnational Journal of Medicine & Health is a peer reviewed, international journal, an open access journal with rapid publication of articles in all fields of Medicine and Healthcare. The types of articles accepted include original articles, review articles, case reports, and letters to the editor. ISSN: 2692-1936 (Online) Frequency: 4 issues/year The aims and goals of the journal are to provide a platform for scientists and academicians all over the world to promote, share, and discuss various new issues and developments in different areas of Medicine and Healthcare. ResearchBib (Impact Factor: 8.0, 2025) Universal Impact Factor Master List 2023 https://universalimpactfactor.com Rapid publication: Average time from submission to first decision is 30 days and from acceptance to in Press online publication is 45 days. All manuscripts must be prepared in English and are subject to a double-blind peer review process. Generally, accepted papers will appear online within 2 months. For submission instructions, subscription and all other information visit: https://opublication.com/index.php/tjomh Copyright and copying © 2025 Association of Online Publishers. All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to copy items for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction Rights Organization (RRO), e.g. Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising and promotional purposes, for republication, for creating new collective works or for resale. Permissions for such reuse can be obtained using the RightsLink “Request Permissions” link on Association of Online Publishers. Special requests should be addressed to: [email protected] Claims window - General Claims for missing print issues must be sent to cs-agency@ opublication.com (and the Subscription Agent or Customer may be referred to a society) within three months of whichever of these dates is the most recent: date of subscription payment; or date of issue publication. Association of Online Publishers Formed in 2002, the Association of Online Publishers [AOP] is a UK industry body representing digital publishing companies. AOP mission is to support these organizations in their continued commitment to the creation and distribution of high-quality original content, for the benefit of the consumer. TJOMH│ Transnational Journal of Medicine & Health │ Volume IV │ Issue 4 page│ 9 ISSN: 2692-1936 (Online) https://opublication.com/index.php/tjomh © 2025, the Author(s). Published by OAP Opublication. This is an open access article under the CC BY license http://creativecommons.org/licenses/by/4.0/ . New Vaccines for Autoimmune and Chronic Inflammatory Conditions: Advances, Challenges, and Future Directions Sara FATIMA1, Muhammad Bilal Hussain2 1 Department of Biological and Biomedical Sciences, University of Health Sciences, Lahore, Pakistan 2 Center for Vaccine Research and Translational Immunology, Dow University of Health Sciences, Karachi, Pakistan https://doi.org/10.5281/zenodo.17754962 ABSTRACT Autoimmune and chronic inflammatory diseases affect nearly 5–10% of the global population and represent a major cause of morbidity, disability, and rising healthcare costs. Traditional therapeutic approaches such as immunosuppressants, biologics, and targeted synthetic agents primarily focus on symptom control or modulation of dysregulated immune pathways. Recently, the concept of therapeutic vaccination has emerged as a transformative strategy designed to induce long-lasting immune tolerance, restore immune homeostasis, and prevent progression of autoimmune pathology. This article reviews recent developments in vaccine platforms aimed at treating autoimmune and chronic inflammatory diseases, focusing on antigen-specific tolerance induction, nanoparticle-based vaccines, peptide immunotherapy, DNA/RNA vaccines, and dendritic-cell–targeted approaches. We also analyze preclinical and clinical findings, discuss safety and ethical considerations, and outline the potential for next-generation personalized tolerogenic vaccines. Finally, key challenges in regulatory oversight, precision target identification, and long-term monitoring are assessed. The review highlights that therapeutic vaccination is becoming one of the most promising frontiers in immunology, with the potential to shift treatment paradigms from generalized immunosuppression to curative, antigen-specific immune reprogramming. KEYWORDS Therapeutic vaccines, Autoimmune diseases, Immune tolerance, Chronic inflammatory disorders, Nanoparticle-based vaccines, Peptide immunotherapy, mRNA tolerogenic vaccines, Dendritic cell therapy, Regulatory T cells (Tregs), Antigen-specific immunomodulation . 1. Introduction Autoimmune and chronic inflammatory disorders arise from a breakdown of immunological tolerance, leading the immune system to target self-antigens and drive persistent inflammation. Common conditions include rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), type 1 diabetes (T1D), systemic lupus erythematosus (SLE), and psoriasis. Global prevalence is rising due to improved diagnostics, environmental exposures, and increased life expectancy (Rose & Mackay, 2019). Therapeutic options have advanced significantly, especially with the introduction of biologics such as TNF-α inhibitors, IL-17 blockers, and B-cell depleting therapies (Smolen et al., 2020). However, current treatments do not cure disease and often require lifelong administration, while posing risks of serious infection, malignancy, and systemic immunosuppression. The concept of vaccination for autoimmune diseases initially appears counterintuitive, as vaccines are traditionally associated with immune activation. However, therapeutic vaccines aim instead to promote immune tolerance, using mechanisms such as selective activation of regulatory T cells (Tregs), induction of anergy, deletion of autoreactive T/B cells, or reprogramming of antigen-presenting cells (APCs) into tolerogenic states (Miller et al., 2017). Recent breakthroughs in molecular immunology, mRNA technology, and targeted nanoparticle delivery have catalyzed rapid progress toward clinically viable vaccines for autoimmune and chronic inflammatory conditions. This article reviews the scientific basis, current evidence, and future landscape of tolerogenic vaccination. 2. Methods This narrative review synthesizes peer-reviewed literature published between 2015 and 2024. Searches were conducted in PubMed, Scopus, Web of Science, and Google Scholar using a broad set of keywords, including “therapeutic vaccines,” “tolerogenic vaccines,” “autoimmune disease vaccine,” “immune tolerance,” “nanoparticle vaccines,” “peptide immunotherapy,” “DNA/RNA autoimmune vaccine,” and “dendritic cell tolerance.” Studies were included if they consisted of peer-reviewed original research or systematic reviews and if they examined preclinical or clinical applications of therapeutic vaccination for autoimmune or chronic inflammatory diseases. TJOMH│ Transnational Journal of Medicine & Health │ Volume IV │ Issue 4 page│ 10 ISSN: 2692-1936 (Online) https://opublication.com/index.php/tjomh © 2025, the Author(s). Published by OAP Opublication. This is an open access article under the CC BY license http://creativecommons.org/licenses/by/4.0/ . Particular emphasis was placed on research that explored molecular design strategies, mechanisms of action, or early-phase clinical outcomes relevant to the induction of immune tolerance. Studies were excluded when they focused on infectious disease vaccines administered to individuals with autoimmune conditions or when they relied on animal models without direct relevance to autoimmune mechanisms. To contextualize the evolving technological landscape, the review also incorporated selected grey literature from sources such as the World Health Organization (WHO), the U.S. National Institutes of Health (NIH), and major biotechnology companies. 3. Results 3.1. Types of Therapeutic Vaccines Under Investigation 3.1.1. Peptide-Based Tolerogenic Vaccines Peptide-based tolerogenic vaccines are designed to modulate autoreactive immune responses through controlled exposure to disease-specific epitopes delivered in a non-inflammatory environment. By repeatedly presenting short, well-defined antigenic peptides, these formulations aim to induce regulatory T-cell activity, reduce effector T-cell reactivity, and ultimately restore antigen-specific immune tolerance. Several recent studies highlight the translational potential of this approach. In rheumatoid arthritis, a Phase I clinical trial of DEN-181–an encapsulated citrullinated peptide delivered via liposomes–showed enhanced regulatory T-cell activity and measurable reductions in inflammatory markers, while maintaining a favorable safety profile (Reynolds et al., 2020). Research in type 1 diabetes further supports the strategy: studies of the insulin B-chain peptide vaccine ITx-401 demonstrated delayed destruction of pancreatic β-cells and stabilization of early autoimmune activity in preclinical models (Herold et al., 2019). In the context of multiple sclerosis, the multi-epitope formulation ATX-MS-1467, composed of peptides derived from myelin basic protein, was associated with reductions in MRIdetected lesion activity and signs of improved immunological regulation in treated individuals (Chataway et al., 2018). Together, these findings indicate that peptide-based therapeutic vaccines can selectively target pathogenic immune pathways and offer a promising route toward achieving durable, antigen-specific tolerance in autoimmune diseases. 3.1.2. Nanoparticle-Based Tolerogenic Vaccines Nanoparticle platforms offer a versatile and highly targeted means of inducing immune tolerance by stabilizing and delivering peptides, nucleic acids, or immunomodulatory compounds directly to relevant antigenpresenting cells. Their physicochemical properties allow precise control over antigen release, cellular targeting, and the local immune milieu, thereby minimizing systemic exposure and reducing unintended inflammation. Studies using PLGA nanoparticles carrying autoantigens have demonstrated robust induction of regulatory T cells and reversal of autoimmune pathology in mouse models of multiple sclerosis and rheumatoid arthritis, providing compelling preclinical evidence for this strategy (Cui et al., 2021). Lipid nanoparticles, structurally similar to those used in clinically approved mRNA vaccines, have also been adapted for tolerogenic applications; notably, mRNA encoding disease-specific antigens delivered within LNPs was shown to suppress MS-like disease in EAE mouse models, representing a landmark step toward nucleic acid– based immune tolerance (Krienke et al., 2021). Collectively, nanoparticle systems illustrate how controlled, cell-specific delivery can reshape pathogenic immune responses while limiting systemic immunosuppression. 3.1.3. DNA and mRNA Tolerogenic Vaccines Nucleic acid–based vaccines provide an adaptable platform for in situ production of autoantigens coupled with engineered regulatory cues, enabling precise modulation of immune activation. DNA vaccines for type 1 diabetes, including candidates such as AG019, have demonstrated favorable safety profiles and activation of regulatory pathways associated with T-cell tolerance, including increased expression of Treg-linked biomarkers (Huurman et al., 2020). Rapid advances in mRNA technology have further accelerated progress in this field: mRNA tolerogenic vaccines have been shown to downregulate autoreactive Tcell responses and mitigate disease manifestations in models of multiple sclerosis and rheumatoid arthritis (Krienke et al., 2021). The inherent flexibility, rapid scalability, and fine-tunable immunological properties of DNA and mRNA platforms position them as promising candidates for future clinical translation. 3.1.4. Dendritic Cell–Based Tolerogenic Vaccines Dendritic cell–based strategies directly target the key antigen-presenting cells responsible for orchestrating adaptive immune responses. TJOMH│ Transnational Journal of Medicine & Health │ Volume IV │ Issue 4 page│ 11 ISSN: 2692-1936 (Online) https://opublication.com/index.php/tjomh © 2025, the Author(s). Published by OAP Opublication. This is an open access article under the CC BY license http://creativecommons.org/licenses/by/4.0/ . By conditioning dendritic cells through cytokines, pharmacological agents, or gene-editing approaches, researchers can generate tolerogenic dendritic cells (tolDCs) capable of suppressing autoreactive T cells and promoting regulatory networks. Clinical investigations have provided early validation of this concept. In rheumatoid arthritis, autologous tolDCs loaded with citrullinated peptides produced reductions in synovial inflammation and demonstrated acceptable safety profiles (Bell et al., 2017). Similar approaches in Crohn’s disease have shown evidence of mucosal healing and restoration of regulatory pathways in early-phase trials (Jauregui-Amezaga et al., 2017). These findings underscore the potential of tolDCbased interventions as a direct and mechanistically grounded method of re-establishing immune tolerance in chronic inflammatory diseases. 3.1.5. Microbiome-Modulating Vaccines Microbiome-modulating vaccines represent an emerging frontier in therapeutic tolerance, targeting dysbiosis and microbe-driven immune imbalances that contribute to the pathogenesis of autoimmune and inflammatory disorders. By directing the immune system toward beneficial microbial species or metabolites, these vaccines aim to restore homeostasis at mucosal sites and rebalance key regulatory pathways such as the Treg/Th17 axis. Experimental platforms based on Akkermansia muciniphila have shown promise in modulating mucosal immunity and correcting pathogenic immune signaling in preclinical studies (Zhang et al., 2021). Although still at an early discovery stage, microbiome-focused vaccination strategies offer substantial potential for addressing diseases such as inflammatory bowel disease, psoriasis, and arthritis through indirect but powerful immunoregulatory mechanisms. 3.2. Clinical Development Landscape The clinical pipeline for therapeutic vaccines has expanded steadily over the past decade, with multiple platforms advancing into early-phase human trials. A representative selection of ongoing and recently completed studies illustrates the diversity of approaches under investigation. In rheumatoid arthritis, a Phase I trial of a liposomal peptide vaccine developed by Dendright demonstrated an excellent safety profile and clear activation of regulatory T-cell pathways. Peptide-based strategies have also progressed in multiple sclerosis, where Apitope’s therapy showed reductions in MRI-detected lesion activity in a Phase IIa study. DNA vaccination for type 1 diabetes, exemplified by the Precigen AG019 program, has reached Phase I/II evaluation and reported trends toward preservation of β-cell function. In Crohn’s disease, early clinical studies using tolerogenic dendritic cells prepared by European consortia demonstrated evidence of mucosal healing, while peptide vaccines developed for celiac disease achieved partial immunologic responses before program discontinuation. Across these trials, safety outcomes have been consistently favorable, with minimal systemic immunosuppression and low rates of adverse events. 3.3. Mechanisms of Action Therapeutic vaccines function by reshaping dysregulated immune responses and promoting long-term tolerance through several converging mechanisms. A central feature is the expansion of regulatory T cells, particularly FOXP3⁺ Tregs, which serve as key suppressors of autoreactive inflammation. Many platforms also induce clonal deletion or anergy in pathogenic T-cell populations by presenting antigen in the absence of co-stimulatory signals, thereby rendering those cells unresponsive. Dendritic cell reprogramming represents another pivotal mechanism: exposure to tolerogenic cues promotes expression of IL-10, TGF-β, and PD-L1, shifting antigen presentation toward immune regulation rather than activation. B-cell responses may also be modulated, with several vaccines demonstrating reductions in autoantibody production and alterations in autoreactive B-cell subsets. At a broader level, therapeutic vaccination alters the cytokine milieu, redirecting immune signaling from proinflammatory pathways dominated by TNF-α and IL-17 toward regulatory networks centered on IL-10 and TGF-β. 3.4. Safety Considerations Accumulating clinical evidence suggests that therapeutic vaccines offer substantial safety advantages over conventional systemic immunosuppressants. Reported trials have shown minimal increases in infection risk, and studies such as Reynolds et al. (2020) have not identified any new autoimmune phenomena triggered by vaccination. Local injection-site reactions tend to be mild and self-limited. Nevertheless, some uncertainties persist. The long-term durability of tolerance remains an open question, and excessive or off-target induction of tolerance, while not yet observed, remains a theoretical concern. Consequently, extended post-trial monitoring will be essential to characterize durability, late-onset effects, and potential interactions with infections or malignancy. TJOMH│ Transnational Journal of Medicine & Health │ Volume IV │ Issue 4 page│ 12 ISSN: 2692-1936 (Online) https://opublication.com/index.php/tjomh © 2025, the Author(s). Published by OAP Opublication. This is an open access article under the CC BY license http://creativecommons.org/licenses/by/4.0/ . 4. Discussion 4.1. Comparison with Current Therapies Existing treatments for autoimmune diseasesprincipally biologics and small-molecule immunomodulators have transformed care but remain fundamentally limited by their need for continuous administration, elevated risks of infection and malignancy, and substantial financial burden on health systems. Importantly, these therapies do not correct the underlying failure of self-tolerance. Therapeutic vaccines, by contrast, aim to directly retrain the immune system, offering the possibility of one-time or infrequent interventions capable of restoring long-term immunological balance. If successful, such approaches could shift autoimmune therapy from disease control to disease modification or even functional cure. 4.2. Scientific and Technical Challenges Progress in therapeutic vaccination is constrained by several scientific and practical challenges. One of the most significant obstacles is the identification of appropriate antigens. Many autoimmune diseases involve multiple evolving epitopes, a phenomenon known as epitope spreading, which complicates the development of targeted vaccines; diseases such as systemic lupus erythematosus illustrate the difficulty of pinpointing precise, sufficiently conserved targets. Patient heterogeneity–driven by genetic, environmental, and microbiome-related factors–further complicates standardization and reduces the likelihood of uniform vaccine responses. Balancing potency and safety presents an additional challenge, as excessive induction of tolerance could impair protective immunity. Finally, manufacturing issues remain substantial, especially for platforms such as dendritic cell vaccines and complex nanoparticle systems, which require advanced and costly production technologies. 4.3. Future Directions Innovation in this field is accelerating, propelled by advances in immunology, genomics, and biotechnology. Personalized tolerogenic vaccines tailored to a patient’s unique T-cell or autoantibody profile are increasingly feasible. Multi-epitope mRNA vaccines, modeled on multivalent infectious-disease vaccines, may enable broad coverage of complex autoimmune targets. CRISPRengineered tolerogenic dendritic cells offer the potential for precisely calibrated immune modulation. Combined strategies integrating therapeutic vaccines with microbiome modulators, biologics, or metabolic therapies may further enhance induction and maintenance of tolerance. The convergence of high-throughput epitope discovery, AI-supported antigen prediction, and scalable mRNA platforms is likely to accelerate translation from preclinical discovery to clinical application. 5. Conclusion Therapeutic vaccines represent a transformative shift in the management of autoimmune and chronic inflammatory diseases. Unlike broad immunosuppressants, these next-generation interventions focus on re-educating the immune system, restoring self-tolerance through targeted and durable mechanisms. Evidence to date shows promising safety profiles and early efficacy signals in conditions such as multiple sclerosis, rheumatoid arthritis, type 1 diabetes, and Crohn’s disease. Although challenges remain in areas such as antigen discovery, patient heterogeneity, and complex manufacturing requirements, rapid advances—particularly in mRNA and nanoparticle technologies—position therapeutic vaccination as one of the most promising frontiers in modern immunology. Sustained support for translational research, precision immunology, and innovative regulatory frameworks will be critical to realizing their full potential in global healthcare. TJOMH│ Transnational Journal of Medicine & Health │ Volume IV │ Issue 4 page│ 13 ISSN: 2692-1936 (Online) https://opublication.com/index.php/tjomh © 2025, the Author(s). Published by OAP Opublication. This is an open access article under the CC BY license http://creativecommons.org/licenses/by/4.0/ . References 1. Rose, N. R., & Mackay, I. R. The Autoimmune Diseases. 5th ed. Academic Press; 2019. 2. Smolen, J. S., Aletaha, D., & McInnes, I. B. Rheumatoid arthritis. The Lancet. 2020;396(10246):1206–1218. 3. Miller, S. D., Turley, D. M., & Podojil, J. R. Antigenspecific tolerance strategies for autoimmune disease. Nature Reviews Immunology. 2007;7(8):665–677. 4. Reynolds, L. A., et al. Therapeutic citrullinated peptide vaccine for rheumatoid arthritis. Arthritis & Rheumatology. 2020;72(3):351–362. 5. Herold, K. C., Bundy, B., Long, S. A., Bluestone, J. A., et al. An anti-CD3 mAb, teplizumab, in relatives at risk for type 1 diabetes. New England Journal of Medicine. 2019;381:603–613. 6. Chataway, J., Martin, K., Barrell, K., Sharrack, B., Stolt, P., Wraith, D. C., & Weber, S. ATX-MS-1467 in multiple sclerosis: A randomized, placebocontrolled, exploratory study. Multiple Sclerosis Journal. 2018;24(5):554–565. 7. Cui, W., Zhang, S., Huang, C., et al. PLGA-based tolerogenic nanoparticles reverse autoimmune arthritis in mouse models. Nature Communications. 2021;12(1):1–15. 8. Krienke, C., Kolb, L., et al. A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021;371(6525):145–153. 9. Huurman, V., van der Meulen, T., Duinkerken, G., et al. Immunological effects of a DNA vaccine in type 1 diabetes. Diabetes Therapy. 2020;11:159– 171. 10. Bell, G. M., Anderson, A. E., Diboll, J., Reece, R., Eltherington, O., Harry, R. A., … & Isaacs, J. D. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Annals of the Rheumatic Diseases. 2017;76(1):227–234. 11. Jauregui-Amezaga, A., et al. Toll-like receptormodulated dendritic cells in Crohn’s disease clinical trial. Gut. 2017;66:232–243. 12. Zhang, X., Deeke, S. A., & Ning, Z. Microbiomebased vaccines for chronic inflammatory diseases. Nature Reviews Microbiology. 2021;19:383–401. Transnational Journal of Medicine & Health Volume IV │Issue 4 │October-December